All In Biotech

Drug Trial Radar · NCT00887536

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Apr 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,613 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,613

Actual

Start

May 2009

Primary completion

Feb 2018

Study completion Feb 2018

Sponsor

Lead sponsor
NSABP Foundation IncResearch network
Sponsor type
Research network
Collaborators
Genentech, Inc.; US Oncology Research
First posted
Apr 24, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this study.

Conditions

  • Breast Cancer

Interventions

  • bevacizumabDrug

    bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab

  • docetaxelDrug

    docetaxel 75 mg/m2 IV every 21 days for 6 cycles

  • doxorubicinDrug

    doxorubicin 50 mg/m2 IV every 21 days for 6 cycles

  • cyclophosphamideDrug

    Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles

  • pegfilgrastimDrug

    pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles \[filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.\]

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive disease-free survival(IDFS)relative to the TAC chemotherapy regimen aloneTime frame: Every 12 months until recurrence

Locations

533 sites in 2 countries. Site status is shown where the registry gives one.

  • Birmingham Hematology and Oncology

    Bessemer, Alabama

  • Birmingham Hematology and Oncology

    Birmingham, Alabama

  • Birmingham Hematology and Oncology - Brookwood

    Birmingham, Alabama

  • Birmingham Hematology and Oncology - Princeton

    Birmingham, Alabama

  • Birmingham Hematology and Oncology - Montclair

    Birmingham, Alabama

  • Birmingham Hematology and Oncology - Pilot

    Birmingham, Alabama

  • Clearview Cancer Institute- Huntsville

    Huntsville, Alabama

  • Northern Arizona Hematology & Onclogy Associates

    Flagstaff, Arizona

  • Arizona Oncolocy (CASA-Green Valley)

    Green Valley, Arizona

  • Arizona Oncology (CASA- Oro Valley)

    Oro Valley, Arizona

  • Hematology Oncology Associates

    Phoenix, Arizona

  • Northern Arizona Hematology & Oncology Associates

    Prescott Valley, Arizona

  • Arizona Oncology (CASA-Safford)

    Safford, Arizona

  • Hematology Oncology Associates

    Scottsdale, Arizona

  • Northern Arizona Hematology & Oncology Associates

    Sedona, Arizona

  • Arizona Oncology Associates - Rudasill

    Tucson, Arizona

  • Arizona Oncology Associates - Carondelet

    Tucson, Arizona

  • Arizona Oncology (CASA-Craycroft)

    Tucson, Arizona

  • Arizona Oncology (CASA-Office Only)

    Tucson, Arizona

  • Arizona Oncology - CASA St. Mary's

    Tucson, Arizona

  • Central Hematology/Oncology Medical Group, Inc.

    Alhambra, California

  • Kaiser Permanente Deer Valley Med Center

    Antioch, California

  • Comp Blook and Cancer Center

    Bakersfield, California

  • Southwest Cancer Care (E. Grand)

    Escondido, California

  • Kaiser Permanente Fremont

    Fremont, California

  • St. Jude Heritage Healthcare

    Fullerton, California

  • Kaiser Permanente Medical Center - Hayward

    Hayward, California

  • Pacific Shores Medical Group

    Huntington Beach, California

  • Southern California Permanente Medical Group

    Irvine, California

  • Wilshire Oncology Medical Group (Business Office)

    La Verne, California

  • Antelope Valley Cancer Center

    Lancaster, California

  • Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center

    Long Beach, California

  • Todd Cancer Institute at Long Beach Memorial Med Cent

    Long Beach, California

  • Pacific Shores Medical Group

    Long Beach, California

  • Pacific Shores Medical Group

    Los Alamitos, California

  • TORI- N Valley Hematology Oncology Med Group

    Mission Hills, California

  • TORI - Oncology Care Medical Assoc.

    Montebello, California

  • Southwest Cancer Care (Medical Center)

    Murrieta, California

  • NValley Hematology/Oncology Medical Group

    Northridge, California

  • Kaiser Permanente-Oakland

    Oakland, California

Showing 40 of 533 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.